CD300LD Inhibitors
CD300LD inhibitors refer to a class of chemical compounds that are designed to interact with the CD300-like family of receptors, which are a subset of the CD300 molecule cluster. These receptors are primarily found on the surface of cells of the immune system, such as natural killer (NK) cells, T cells, B cells, mast cells, neutrophils, and monocytes. The CD300LD family of receptors is involved in a variety of immune system regulatory processes. They are known for their role in modulating both activating and inhibitory signals within immune cells, which can influence the immune response. The "LD" in CD300LD stands for "like domains," referring to the structural similarity these receptors have with the prototypical CD300 molecule.
Inhibitors targeting the CD300LD receptors are specialized molecules that interact with these receptors to modulate their activity. The structure of these inhibitors is designed to bind specifically to the CD300LD receptors, usually at the sites where natural ligands would typically attach, thereby preventing the natural interaction and subsequent signal transduction. The precise mechanism of these inhibitors can vary, but generally, they stabilize the receptors in an inactive state or prevent their aggregation or association with other key signaling molecules. The CD300LD inhibitors are significant in the context of immune regulation because they directly affect the signaling pathways that are crucial for the function and response of immune cells. By inhibiting CD300LD receptors, these compounds can influence the balance between activation and inhibition signals transmitted through the receptors, thereby altering the immune cell responses.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, indirectly modulates CD300LD by disrupting B-cell receptor (BCR) signaling. Inhibiting BTK interferes with downstream pathways, influencing cellular processes related to CD300LD. This highlights the potential crosstalk between BCR signaling and CD300LD function, providing insights into the regulatory mechanisms governing CD300LD within the context of B-cell signaling networks. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363, a selective AKT inhibitor, indirectly influences CD300LD by targeting the PI3K/AKT/mTOR pathway. Inhibiting AKT disrupts downstream signaling, impacting cellular processes related to CD300LD. This indirect modulation sheds light on the potential involvement of PI3K/AKT/mTOR signaling in regulating CD300LD function within the context of intracellular signaling networks. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $184.00 $195.00 | 2 | |
GDC-0941, a selective PI3K inhibitor, indirectly influences CD300LD by targeting the PI3K/AKT/mTOR pathway. Inhibiting PI3K disrupts downstream signaling, influencing cellular processes related to CD300LD. This indirect modulation provides insights into the interconnectedness of intracellular signaling networks and CD300LD regulation. | ||||||
R406 | 841290-81-1 | sc-364595 sc-364595A | 2 mg 10 mg | $160.00 $370.00 | 16 | |
R406, a spleen tyrosine kinase (SYK) inhibitor, indirectly modulates CD300LD by disrupting SYK-dependent signaling pathways. Inhibiting SYK interferes with downstream pathways, influencing cellular processes related to CD300LD. This indirect regulation reveals potential connections between SYK signaling and CD300LD function, offering insights into the regulatory mechanisms governing CD300LD within the context of immune cell signaling. | ||||||
VX-11e | 896720-20-0 | sc-507301 | 10 mg | $180.00 | ||
VX-11e, a BRD4 inhibitor, indirectly influences CD300LD by disrupting chromatin-mediated regulation. Inhibiting BRD4 modulates gene expression patterns, potentially impacting cellular processes related to CD300LD. This epigenetic modulation sheds light on the intricate regulatory networks that may govern CD300LD expression and function within the context of chromatin dynamics. | ||||||
Syk Inhibitor IV, BAY 61-3606 HCl | 732983-37-8 | sc-202351 | 2 mg | $321.00 | 25 | |
BAY 61-3606, a Syk inhibitor, indirectly modulates CD300LD by disrupting Syk-dependent signaling pathways. Inhibiting Syk interferes with downstream pathways, influencing cellular processes related to CD300LD. This indirect regulation provides insights into the potential roles of Syk signaling in regulating CD300LD function within the context of immune cell signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly influences CD300LD by targeting the mTOR pathway. Inhibiting mTOR disrupts downstream signaling, impacting cellular processes related to CD300LD. This indirect modulation provides insights into the potential involvement of mTOR signaling in governing CD300LD function within the context of intracellular signaling networks. | ||||||
TG100-115 | 677297-51-7 | sc-364634 sc-364634A | 5 mg 100 mg | $245.00 $1836.00 | 1 | |
TG100-115, a JAK2/FLT3 inhibitor, indirectly influences CD300LD by targeting the JAK/STAT pathway. Inhibiting JAK2 disrupts downstream signaling, impacting cellular processes related to CD300LD. This indirect modulation provides insights into the potential involvement of JAK/STAT signaling in regulating CD300LD function within the context of intracellular signaling networks. | ||||||
SB 218078 | 135897-06-2 | sc-203692 | 1 mg | $133.00 | 1 | |
SB-218078, a JAK3 inhibitor, indirectly modulates CD300LD by targeting the JAK/STAT pathway. Inhibiting JAK3 interferes with downstream pathways, influencing cellular processes related to CD300LD. This indirect regulation reveals potential connections between JAK/STAT signaling and CD300LD function, offering insights into the regulatory mechanisms governing CD300LD within the context of immune cell signaling. | ||||||
Cyt387 | 1056634-68-4 | sc-364733 sc-364733A | 10 mg 50 mg | $210.00 $600.00 | 2 | |
CYT387, a JAK1/2 inhibitor, indirectly influences CD300LD by targeting the JAK/STAT pathway. Inhibiting JAK1/2 disrupts downstream signaling, impacting cellular processes related to CD300LD. This indirect modulation provides insights into the potential regulatory roles of JAK/STAT signaling in governing CD300LD function within the context of intracellular signaling networks. | ||||||